Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis

This is not the most recent version

Information

DOI:
https://doi.org/10.1002/14651858.CD004197.pub3Copy DOI
Database:
  1. Cochrane Database of Systematic Reviews
Version published:
  1. 07 October 2009see what's new
Type:
  1. Intervention
Stage:
  1. Review
Cochrane Editorial Group:
  1. Cochrane Cystic Fibrosis and Genetic Disorders Group

Copyright:
  1. Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Article metrics

Altmetric:

Cited by:

Cited 0 times via Crossref Cited-by Linking

Collapse

Authors

  • Simon C Langton Hewer

    Correspondence to: Paediatric Respiratory Medicine, Bristol Royal Hospital for Children, Bristol, UK

    [email protected]

  • Alan R Smyth

    Department of Child Health, School of Clinical Sciences & Nottingham Respiratory BRU, University of Nottingham, Nottingham, UK

Contributions of authors

Damian Wood wrote the first draft of the review. Both Damian Wood and Alan Smyth edited it to produce the final version. Both Damian Wood and Alan Smyth have worked on updated versions of the review. As from Issue 2, 2009 the new lead author is Simon Langton Hewer, who drafted the updated review with input from Alan Smyth.

Simon Langton Hewer acts as guarantor of the review.

Declarations of interest

Dr Langton Hewer is the lead investigator on the trial Torpedo‐CF: Trial of Optimal Therapy for Pseudomonas Eradication in Cystic Fibrosis.

Dr Smyth has received financial support from Forest Laboratories and Profile Pharma (both companies market a nebulised colistin product) and from Chiron (manufacturers of the TOBI® brand of nebulised tobramycin).

Acknowledgements

Hazel Bunn assisted in formulation of the review protocol. We would also like to thank Dr Damian Wood for his input into the original version of this review and subsequent updates until November 2007.

Version history

Published

Title

Stage

Authors

Version

2023 Jun 02

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis

Review

Simon C Langton Hewer, Sherie Smith, Nicola J Rowbotham, Alexander Yule, Alan R Smyth

https://doi.org/10.1002/14651858.CD004197.pub6

2017 Apr 25

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis

Review

Simon C Langton Hewer, Alan R Smyth

https://doi.org/10.1002/14651858.CD004197.pub5

2014 Nov 10

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis

Review

Simon C Langton Hewer, Alan R Smyth

https://doi.org/10.1002/14651858.CD004197.pub4

2009 Oct 07

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis

Review

Simon C Langton Hewer, Alan R Smyth

https://doi.org/10.1002/14651858.CD004197.pub3

2009 Jul 08

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis

Review

Damian M Wood, Alan R Smyth

https://doi.org/10.1002/14651858.CD004197.pub2

2003 Apr 22

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis

Protocol

Damian M Wood, Alan R Smyth

https://doi.org/10.1002/14651858.CD004197

Differences between protocol and review

2009

After new lead reviewer re‐assessed the review, the section 'Objectives' was expanded to include the sentence:

'To investigate whether there is evidence of superiority or improved cost‐effectiveness between antibiotic strategies.'

2005

Two clinically relevant additional outcomes were added at review stage to the ones we had originally listed:

  1. Time to chronic infection (defined as the presence of P. aeruginosa in each monthly sputum sample for six consecutive months or the presence of precipitating antibodies to P. aeruginosa or both)

  2. Clinical and radiological scores

Currently, we have included both P. aeruginosa free and P. aeruginosa naive patients according to the definition by Lee (Lee 2003). At the update in 2009 we have added plans to analyse these subgroups separately if sufficient data become available from included studies in the future.

PICOs

Population
Intervention
Comparison
Outcome

The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.

See more on using PICO in the Cochrane Handbook.